Nϵ-(carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function

Wagner, Zoltán; Wittmann, István; Mazák, István; Schinzel, Reinhard; Heidland, A.; Kientsch-Engel, Rosemarie; Nagy, Judit

doi:10.1053/ajkd.2001.27695

Cited by 92 publications

(76 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were described for T1D and T2D patients (r = 0.84; P < 0.001) (26,27). In contrast, a significant positive correlation between low molecular weight serum F-AGEs and serum creatinine was shown in individuals with only minimal renal disturbance or with normal creatinine concentrations (28).…”

Section: Resultssupporting

confidence: 80%

“…Therefore, decreased glomerular filtration rate and tubule cell damage could also be involved in AGE accumulation, as suggested by Wagner and cols. (27), who showed that patients with impaired renal function presented with increased serum CML and F-AGE concentrations and decreased creatinine clearance. In the present study, it is not clear why GDM pregnant women with normal serum creatinine concentrations presented with increased AGE concentrations, and more studies are necessary to determine the extent to which these findings are repeated elsewhere.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients

Júnior

Brescansin

Santos-Weiss

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objectives: Advanced glycation end products (AGEs) are involved in the pathogenesis and complications of diabetes mellitus (DM). Gestational DM (GDM) is characterized by increased glycemia and oxidative stress, which are factors associated with high serum AGE concentrations. The aim of this study was to evaluate the utility of a serum fluorescence AGE (F-AGE) method as a screening tool for gestational diabetes. Subjects and methods: Serum samples from 225 GDM patients and 217 healthy pregnant women (healthy controls) were diluted 50-fold in phosphate-buffered saline, and the AGEs were estimated by fluorometric analysis (λ Ex 350 nm/ λ Em 440 nm). Results: No significant (P > 0.05) differences in AGE concentrations, expressed in Arbitrary Units (UA/mL × 10 4 ), were observed in the women with GDM or in the healthy controls. Furthermore, F-AGE concentrations did not change significantly during the pregnancy (12-32 weeks of gestation). Only the GDM group had a positive correlation (r = 0.421; P < 0.001) between F-AGEs and serum creatinine concentrations. Conclusion: It was not possible to distinguish women with gestational diabetes from the healthy controls on the basis of serum F-AGE concentrations. Arch Endocrinol Metab. 2017;61(3):233-7.

show abstract

Section: Resultssupporting

confidence: 80%

Section: Resultsmentioning

confidence: 99%

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients

Júnior

Brescansin

Santos-Weiss

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…neuropathy) even before clinical manifested diabetic renal disease. Other reports have not found significant increased fluorescent AGE [6,14] in the presence of clinical diabetic complications (retinopathy, neuropathy).…”

Section: Discussionmentioning

confidence: 78%

“…Creatinine clearance (Cl Cr , ml/min) was estimated using Cockcroft-Gault formula [(140-age) x weight]/72 x serum creatinine (S Cr , mg/100 ml). For women, the value given by this equation was multiplied by 0.85 [14]. Total cholesterol (T-Cho), triglycerides (Tg), and hemoglobin (Hb A C1 ) were determined for all patients in blood samples collected after an overnight fast (at least 12 h).…”

Section: Characterization Of Subjectsmentioning

confidence: 99%

Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients

Heltianu¹,

Manea²,

Guja³

et al. 2008

Open Life Sciences

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) are involved in the occurrence of vascular complications in diabetes. The present study was undertaken to investigate the level of low-molecular weight products of AGEs (LMW-AGEs) in relation to microvascular complications in type 1 diabetes, and the possible relationship with nitric oxide (NO) as a marker of endothelial function. Patients with normal renal function (NRF) were classified into two groups: (1) without, and (2) with diabetic neuropathy; and patients with renal impairment also into two groups: (3) diabetic renal disease, and (4) end-stage renal disease. The fluorescence of LMW-AGEs and measurement of NO metabolites was assessed in 277 serum samples. In addition, multiple regression analysis was performed. In group 1, LMW-AGEs level (9.3±1.1 AF%) was higher than in the control group (2.4±0.3 AF%). A trend in the increase of LMW-AGEs with neuropathy (29.7±5.5 AF%, group 2), and further with renal impairment (47.0±8.0, group 3 and 137.8±25.5 AF%, group 4), was observed. In multivariate regression analysis LMW-AGEs were associated with NO metabolites in group 2. In NRF patients, diabetic neuropathy was significantly correlated with LMW-AGEs and NO metabolites, independently of serum creatinine and duration of diabetes. This relationship suggests that the NO and LMW-AGEs' actions (possibly synergistic) in endothelial activation possess a role in the initiation and development of diabetic microvascular complications.

show abstract

“…However, this is the first time that an increase in all three AGE subtypes has been demonstrated in ZDF rats, an increase that was suppressed simultaneously by drug intervention. In patients with diabetic nephropathy, urinary excretion of CML is reduced, and insufficient clearance may result in increased serum AGE concentrations as well as tissue accumulation of AGEs [26][27][28][29]. This is further supported by the fact that the AGE inhibitor aminoguanidine improved renal function in diabetic nephropathy, reduced tissue AGE deposits [30][31][32] and increased urinary excretion of dietary AGEs [33].…”

Section: Discussionmentioning

confidence: 91%

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition

Wihler¹,

Schäfer²,

Schmid³

et al. 2005

Diabetologia

View full text Add to dashboard Cite

Aims/hypothesis: Renal accumulation of AGEs may contribute to the progression of diabetic nephropathy. We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-imidazolone, carboxymethyllysine (CML) and pentosidine, and on clearance of CML in type 2 diabetes. Methods: Male Zucker diabetic fatty rats (ZDF, Gmi-fa/fa) rats were treated from age 10 to 37 weeks with ramipril (1 mg·kg −1 ·day −1 ), AVE7688 (45 mg·kg −1 ·day −1 ) or without drug. Ramipril and AVE7688 reduced albuminuria by 30 and 90%, respectively. Results: ZDF rats showed increased renal accumulation of the AGE subtypes 3-deoxyglucosone-imidazolone, pentosidine and CML by about 40, 55 and 55%, respectively compared with heterozygous, non-diabetic control animals at the age of 37 weeks. AVE7688 but not ramipril attenuated the renal accumulation of 3-deoxyglucosone-imidazolone, pentosidine and CML and improved CML clearance in ZDF rats. During glycation reactions in vitro, AVE7688 also demonstrated potent chelating activity and inhibited metal-catalysed formation of pentosidine and CML. Conclusions/interpretation: Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 diabetes.

show abstract

Nϵ-(carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function

Cited by 92 publications

References 20 publications

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients

Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition

Contact Info

Product

Resources

About